Levosert One (Levonorgestrel)

Levonorgestrel, a progestin hormonal contraceptive, is used to prevent pregnancy.

• Contraception: provides up to three years of reliable pregnancy prevention when placed correctly in the uterus.

• Levosert One releases levonorgestrel locally from the intrauterine system at approximately 20 µg per day. The hormone thickens cervical mucus, reduces sperm motility and viability, and suppresses endometrial proliferation, creating an environment that prevents fertilisation and implantation.

Levosert One may cause a range of adverse reactions, most of which are mild and related to the device or hormone release.

Common Side Effects

• Irregular vaginal bleeding or spotting: changes in bleeding pattern are frequent during the first months.
• Amenorrhea: absence of periods may occur after continued use.
• Pelvic or abdominal pain: discomfort around the insertion site is common.
• Device expulsion: the IUS may be partially or fully expelled.
• Insertion site irritation: local soreness or swelling after placement.
• Hormonal effects: acne, breast tenderness, or mood changes.

Serious or Rare Side Effects

• Uterine perforation: a rare event during insertion that can cause abdominal injury.
• Pelvic infection: severe infection requiring medical treatment.
• Ectopic pregnancy: occurs if pregnancy happens despite the device.
• Severe allergic reaction: anaphylaxis or hypersensitivity to levonorgestrel or device materials.
• Device migration: movement of the IUS from its intended position.
• Heavy bleeding: unexpected profuse bleeding that may need intervention.

Before using Levosert One, clinicians should assess patient history and ensure appropriate conditions are met.

• Pregnancy contraindication: do not insert in a known or suspected pregnancy.
• Uterine abnormalities: avoid placement in women with fibroids, congenital anomalies, or significant scarring.
• Active pelvic infection: postpone insertion until infection resolves.
• Unexplained vaginal bleeding: investigate before device placement.
• Follow‑up checks: schedule routine examinations to confirm correct IUS position.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levosert One may interact with medications that affect levonorgestrel metabolism or hormone balance.

Major Interactions (Avoid)

• Rifampin, carbamazepine, phenytoin, or St. John's wort: strong enzyme inducers that can markedly reduce levonorgestrel levels.
• Antifungal agents such as ketoconazole: may increase systemic exposure.

Moderate Interactions (Monitor Closely)

• Antiretroviral drugs (e.g., efavirenz): may modestly lower hormone concentrations.
• Certain antibiotics (e.g., griseofulvin): limited effect but monitoring is advised.
• Hormonal therapies (e.g., estrogen‑containing products): may alter bleeding patterns and require clinical observation.